Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
30 Julio 2024 - 8:10AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company focused on development and commercialization of
ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the
treatment of retina diseases, today announced that Russell Trenary,
President and Chief Executive Officer of Outlook Therapeutics will
participate in a fireside chat at the BTIG Virtual Biotechnology
Conference 2024 on Monday, August 5, 2024 at 8:00 AM ET.
In addition to the fireside chat, management
will be available to participate in virtual one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference. If you are interested in scheduling a
meeting with Outlook Therapeutics during the conference, please
reach out to your BTIG representative.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company focused on the development and commercialization of
ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the
treatment of retina diseases, including wet AMD. LYTENAVA™
(bevacizumab gamma) is the first ophthalmic formulation of
bevacizumab to receive European Commission and United Kingdom
Marketing Authorization for the treatment of wet AMD. Outlook
Therapeutics is working to initiate its commercial launch of
LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment
for wet AMD in the first calendar quarter of 2025. In the United
States, ONS-5010/LYTENAVA™ is investigational, is being evaluated
in an ongoing non-inferiority study for the treatment of wet AMD,
and if successful, the data may be sufficient for Outlook to
resubmit a BLA application to the FDA in the United States. If
approved in the United States, ONS-5010/LYTENAVA™, would be the
first approved ophthalmic formulation of bevacizumab for use in
retinal indications, including wet AMD.
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Outlook Therapeutics (NASDAQ:OTLK)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024